Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PVCT $1.00 0.1399 +16.27%
ONCY $0.82 0.1020 +14.21%
BIND $8.94 1.1100 +14.18%
INCY $64.18 6.3100 +10.90%
XLRN $38.24 3.5000 +10.07%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CNDO $1.70 -0.1000 -5.56%
AEZS $1.06 -0.0500 -4.50%
ARGS $9.66 -0.3600 -3.59%
APRI $1.58 -0.0500 -3.07%
CRIS $1.27 -0.0400 -3.05%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

FDA Approves XenoPort, Glaxo Drug For Restless Leg Syndrome

(NASDAQ/Dow Jones Newswires) Apr 6, 2011 - The Food and Drug Administration has approved Horizant, a drug for restless legs syndrome that XenoPort Inc. and GlaxoSmithKline PLC developed together, the companies said in a release.
read article 



Pfizer, Biotech Partner to Develop Drugs for Rare Diseases

(Wall Street Journal) Apr 6, 2011 - Pfizer Inc. is teaming up with a biotechnology firm in an unusual early-stage drug-development deal that could be worth as much as $210 million and bolster the drug giant's new push into rare diseases.
read article (paid subscription required) 



Valeant CEO Spurns Drug Research for Hostile Cephalon Deal as Shares Climb

(Bloomberg) Apr 7, 2011 - Valeant Pharmaceuticals International Inc. Chief Executive Officer J. Michael Pearson has built the little-known Canadian drugmaker into a stock- market favorite with 21 friendly acquisitions for $1.8 billion since he took over in 2008.
read article 



Radiologists Urge Referring Physicians to Use Latest Version of ACR Appropriateness Criteria

(ACR) Apr 7, 2011 - New evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam for a patient’s clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria®.
read press release 



Budget Cuts Pose Risk to Cancer Research

(ASCO in Action) Apr 6, 2011 - As a member of One Voice Against Cancer (OVAC), ASCO and other cancer advocates co-signed a letter to legislators urging them to restore the funding that was cut in H.R. 1 for programs that have been successful in contributing towards the progress against cancer.
read article 



Op-Ed: Medicine on the Move

(New York Times) Apr 6, 2011 - Sometimes you really do want to tell the medical profession to just make up its mind.
read article (paid subscription required) 



Granisol™ (Granisetron) Oral Solution Eligible for Medicaid Reimbursement

(PediatRx) Apr 6, 2011 - PediatRx, Inc. announced that the U.S. Centers for Medicare and Medicaid Services (CMS) recently notified state Medicaid agencies to include PediatRx’s GRANISOL, NDC 52547-0801-30, in their list of reimbursed products.
read press release 



Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells

(MSN Money) Apr 7, 2011 - Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc., today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.
read article 



Myriad Partners with BioMarin on PARP Inhibitor

(GenomeWeb News) Apr 7, 2011 - Myriad Genetics has signed an agreement with BioMarin Pharmaceutical to perform BRCA1 and BRCA 2 mutation testing for the drug firm's PARP inhibitor drug candidate, Myriad said after the close of the market on Wednesday.
read article (free registration required) 



SuperGen and Astex Therapeutics Enter Definitive Merger Agreement

(SuperGen) Apr 6, 2011 - SuperGen, Inc. and Astex Therapeutics Limited jointly announce today that they have entered into a definitive agreement to merge the two companies, subject to customary closing conditions, including regulatory and shareholder approvals.
read press release 



Company Sees Bankruptcy as Boon to Cancer Vaccine

(WSJ/Bankruptcy Beat Blog) Apr 5, 2011 - To hear Sam Duffy tell it, bankruptcy was the best thing that could have happened to Biovest International Inc.
read article (paid subscription required) 



AstraZeneca’s Victory Highlights Difficulty Of Cancer Drug Development

(Forbes/The Medicine Show Blog) Apr 6, 2011 - Will the restrictions on vandetanib be so tough that it will be difficult to sell? Or will a high price make up for the hurdles?
read article 



URMC Urology Team Introduces Breakthrough Surgery for Kidney Cancer

(URMC) Apr 7, 2011 - James P. Wilmot Cancer Center surgeons have become the first in the nation to use a new, infrared imaging technique combined with robot-assisted surgery to remove kidney cancer.
read press release 



Test Detects Aggressive Prostate Cancer

(UPI) Apr 7, 2011 - A new prostate specific antigen test to screen for prostate cancer is more accurate in detecting more aggressive prostate cancer, U.S. researchers say.
read article 



U. Researchers Find Association Between Parkinson’s, Prostate Cancer

(Deseret News) Apr 7, 2011 - University of Utah Medical School researchers have found evidence that Parkinson's disease is associated with an increased risk for prostate cancer and for melanoma. That increased risk also extends to close and more distant relatives.
read article 



Study Lifts Hopes for Roche Successor to Herceptin

(Reuters) Apr 7, 2011 - Breast cancer patients given Roche's experimental drug T-DM1 lived longer with their disease under control and had fewer side effects than those on standard treatment of Herceptin plus chemotherapy, a mid-stage trial showed.
read article 



FDA Approves First Drug for Form of Thyroid Cancer

(Los Angeles Times) Apr 6, 2011 - Federal regulators Wednesday approved the first drug treatment for a rare form of late-stage thyroid cancer.
read article (free registration required) 



Breast-Cancer Link to Paxil Drug Category Found in Antidepressant Research

(Bloomberg) Apr 7, 2011 - Scientists should more closely examine whether antidepressant drugs increase the risk of breast and ovarian cancer, according to a researcher affiliated with Harvard University whose review of 61 studies suggested a link.
read article 



FDA Approves Orphan Drug Vandetanib

(AstraZeneca) Apr 7, 2011 - AstraZeneca today announced that the US Food and Drug Administration (FDA) approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.
read press release 



FDA Declines To Widen Merck's Gardasil To Women Older Than 26

(Morningstar/Dow Jones Newswires) Apr 6, 2011 - Merck & Co. said the U.S. Food and Drug Administration failed to widen the indication of its Gardasil vaccine to prevent cancers linked to human papillomavirus in women above the age 26.
read article 



Roche Announces Positive Phase II Results for Trastuzumab Emtansine (T-DM1) in HER2-positive Metastatic Breast Cancer

(Roche) Apr 7, 2011 - Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
read press release 



FDA Approves New Treatment for Rare Form of Thyroid Cancer

(FDA) April 6, 2011 - The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.
read press release 



FDA Approves New Treatment for Rare Form of Thyroid Cancer

(FDA) April 6, 2011 - The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.
read press release 



FDA Panel Unanimously Backs Optimer Antibiotic

(Bloomberg Businessweek) Apr 5, 2011 - A panel of federal health experts on Tuesday unanimously endorsed Optimer Pharmaceutical's experimental antibiotic to prevent infection of the digestive tract.
read article 



Cephalon Board Rejects Valeant’s Unsolicited $5.7 Billion Bid As Too Low

(Bloomberg) Apr 6, 2011 - Four months after its founder and chief executive officer passed away, Cephalon Inc. is battling a $5.7 billion hostile bid from Valeant Pharmaceuticals International Inc., saying the offer is too low.
read article